Studying Attention and Eye Movement in Parkinson's Disease and Related Movement Disorders
Studies how deep brain stimulation affects eye movement and facial expression perception in Parkinson's disease.
Key facts
- Who runs it
- University of Nebraska
- Where
- Omaha, United StatesSee the site
- Trial code
- Registry title
- Attention and Eye Movement in Parkinson's Disease
- Status
- Recruiting
- People taking part
- 138 people, planned
- Started
- 22 Sept 2025
- Expected to end
- Aug 2028
- Type of study
- Interventional
- Treatments tested
- Normal therapeutic DBS
- Reduced current DBS
- Reduced frequency DBS
- Record updated
- 5 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with Parkinson's disease, essential tremor or dystonia who are getting a deep brain stimulation (DBS) device, plus age-paired people without these conditions.
- Age
- 19 to 90 years.
- Sex
- Both men and women can join.
- Disease stage
- Idiopathic Parkinson's disease, essential tremor or dystonia. Planned for a new DBS implant in the subthalamic nucleus, the ventral intermediate nucleus of the thalamus or the internal globus pallidus.
- Earlier treatment
- Comparison participants must have no history of a neurodegenerative disorder. For the operating room part, people are scheduled for awake DBS implantation. For the stimulation-change part, people must be willing and able to tolerate brief changes of DBS settings.
Main reasons for not taking part
- Eyesight, even when corrected, too poor to judge faces on a screen
- Cannot understand the task instructions or complete the tasks
- Motor symptoms not controlled well enough to press a button or use a mouse slider
- Not having an awake DBS implantation (for the operating room part)
- DBS gave no helpful effect on motor symptoms (for the stimulation-change part)
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- All Participants (Aim 1):; Ability and willingness to provide signed informed consent for this study; Ability to express perceptual judgments through a button press or mouse- controlled computerized slider; Age 19 - 90 years
- DBS Participants (Aim 1):; Diagnosis of idiopathic Parkinson's disease (PD), essential tremor (ET) or dystonia (DT); Scheduled for new implantation of a therapeutic DBS device targeted to subthalamic nucleus (STN), ventral intermediate nucleus of thalamus (VIM) or internal globus pallidus (GPi)
- Comparison Participants (Aim 1):; o Selection by age matching to participants in PD group
- Parkinson's disease (PD), essential tremor (ET) and dystonia (DT) Participants (Aim 2):; Ability and willingness to provide signed informed consent for this study; Ability to express perceptual judgments through a button press or mouse- controlled computerized slider; Age 19 - 90 years; Scheduled for awake DBS implantation with clinical micro-electrode recordings (MER); Willing and able to engage in tasks during an awake surgical procedure
- Parkinson's disease (PD), essential tremor (ET) and dystonia (DT) Participants (Aim 3):; Ability and willingness to provide signed informed consent for this study; Ability to express perceptual judgments through a button press or mouse- controlled computerized slider; Age 19 - 90 years; Willing to undergo acute manipulations of DBS; Able to tolerate acute changes of DBS
Who cannot take part
- Healthy Comparison Participants (Aim 1):; o History of neurodegenerative disorder
- Parkinson's disease (PD), essential tremor (ET) and dystonia (DT) Participants (Aim 2):; Corrected visual acuity insufficient to perceptually judge face stimuli; Inability to understand task instructions or complete task requirements; Not undergoing awake DBS implantation; Uncorrected visual acuity insufficient to perceptually judge face stimuli
- Parkinson's disease (PD), essential tremor (ET) and dystonia (DT) Participants (Aim 3):; Corrected visual acuity insufficient to perceptually judge face stimuli; Inability to understand task instructions or complete task requirements; Failure of DBS to achieve a therapeutic effect on motor symptoms
- All Participants (Aim 1):; Corrected visual acuity insufficient to perceptually judge face stimuli; Inability to understand task instructions or complete task requirements
- DBS Participants (Aim 1):; o Insufficient therapeutic control of motor symptoms to engage in tasks requiring button press or use of a mouse to control a slider
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 19 and 90 years old?
Where in United States
- University of Nebraska Medical CenterOmaha, United StatesContact: Dulce V Maroni, PhDTaking people
About the trial
What the trial wants to find out
The goal of this observational and interventional study is to understand how therapeutic deep brain stimulation (DBS) affects attention, perception and cognition in participants with Parkinson's disease (PD) and non-PD movement disorders, including essential tremor (ET) and dystonia (DT). The main questions it aims to answer are:
Read full original descriptionShow less
* Does impaired control of attention and eye movement in PD alter how social cues are perceived and interpreted? * Does therapeutic DBS improve or worsen attentional and perceptual deficits for social cues in PD, ET and DT? * Can DBS be optimized to restore normal attentional control in PD while remaining an effective therapy for other aspects of the disorder. * What do parts of the brain targeted by DBS contribute to the control of attention?
Using an eye tracking camera, investigators will study how participants with PD, ET and DT look at and perceive facial expressions of emotion before and after starting DBS therapy, in comparison to a group of healthy participants without ET, PD, DT or DBS. Participants with PD, ET and DT will see and rate morphed facial expressions on a computer screen in three conditions:
* Before starting DBS therapy (over approximately 1 hour). * In the operating room, during the standard procedure to implant DBS electrodes, while the participant is awake (for no more than 15 minutes). * After starting DBS therapy, with brief experimental changes of DBS stimulation level and frequency (over approximately 1 hour).
The group in the trial
- Acute alteration of DBSTreatment being tested
All participants in the single arm of this study will undergo acute alteration of DBS stimulation under three conditions in randomized order over the course of 1 hour.
Treatment: Normal therapeutic DBS, Reduced current DBS, and Reduced frequency DBS
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Investigating the Role of Attention in Perceptual and Cognitive Consequences of Parkinson's Disease
- Plain-language title
- Studying Attention and Eye Movement in Parkinson's Disease and Related Movement DisordersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06899022, who can take part
- Record updated
- 5 May 2026